NCT04236778View on ClinicalTrials.gov

First-in-human Study of VE303 in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

November 28, 2017

Primary Completion Date

March 11, 2019

Study Completion Date

March 11, 2019

Conditions
Healthy Volunteers
Interventions
DRUG

VE303

The VE303 Drug Product is a live biotherapeutic product (LBP) consisting of 8 clonal human commensal bacterial strains manufactured under GMP conditions.

DRUG

Oral Vancomycin

Vancomycin, when taken by mouth, is used to treat Clostridium difficile-associated diarrhea.

Trial Locations (1)

21201

Pharmaron CPC, Baltimore

All Listed Sponsors
lead

Vedanta Biosciences, Inc.

INDUSTRY

NCT04236778 - First-in-human Study of VE303 in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter